

February 14, 2018

To,

BOMBAY STOCK EXCHANGE LIMITED	NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Phiroze Jeejeebhoy Tower, Dalal Street, Fort, Mumbai – 400 001	Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051
Scrip Code : 532908	Scrip ID : SHARONBIO

Dear Sir/Madam,

Sub: Notice for Adoption of Financial Results for quarter ended June 30, 2017, September 30, 2017 & December 31, 2017

We hereby inform you that Corporate Insolvency Resolution Process ("CIRP") has been initiated in respect of Sharon Bio-Medicine Limited ("the Company") under the provisions of Insolvency and Bankruptcy Code, 2016 ("IBC") by an order of National Company Law Tribunal ("NCLT") with effect from April 11, 2017.

As per section 17 of the IBC, 2016, the powers of the Board of Directors stands suspended, and such powers shall be vested with the Resolution Professional appointed for the Company.

Pursuant to Regulation 29(1) (a) of the SEBI (listing obligations and disclosure requirements) Regulations 2015, this is to inform you that Resolution Professional on Thursday, February 22, 2018 at 03.00 PM, will consider the Unaudited Financial Results of the Company for the Quarter ended on June 30, 2017, September 30, 2017 & December 31, 2017.

In connection with the above, as per the company's code of conduct to regulate, monitor and report trading by insiders, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the Company will be closed from February 15, 2018 to February 24, 2018 (both days inclusive) for the purpose of declaration of financial results of the Company for the quarter ended on June 30, 2017, September 30, 2017 & December 31, 2017. Accordingly, all the Designated Employees of the Company have been intimated not to enter into any transaction involving the securities of the Company during the aforesaid period of closure of trading window.

Further, please note that the Company has already made necessary arrangement to publish the same in the newspaper as required under SEBI (LODR), Regulations, 2015.

This is for your information and record.

For Sharon Bio-Medicine Limited



Deepali Bhatia
Company Secretary & Compliance Officer



Adm. Off. : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705.
Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001
www.sharonbio.com

CIN NO. L24110MH1989PLC052251

Caring for relationships



Sharon

BIO-MEDICINE LTD.

CIN:L24110MH1989PLC052251

Registered Office: W-34 & W-34/1, MIDC, TALOJA, DIST-RAIGAD.

Tel No.91-22 67944000 Fax No.91-22 67944001

Email:finance@sharonbio.com, Web:www.sharonbio.com

NOTICE

Notice is hereby given pursuant to Regulation 47(1)(a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, that Resolution Professional, on Thursday, February 22, 2018 at 03.00 PM, will consider and approve the Unaudited Financial Results for the Quarter ended June 30, 2017, September 30, 2017 & December 31, 2017.

Sharon Bio-Medicine Limited ("the Company") is under Corporate Insolvency Resolution Process under the provisions of Insolvency and Bankruptcy Code, 2016 (IBC) by an order of National Company Law Tribunal with effect from April 11, 2017.

Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window in respect of dealing in the Equity Shares of the Company, will remain closed, for all the Directors, Designated (specified) Employees of the Company and "connected persons" with the Company, with effect from February 15, 2018 to February 24, 2018 (both days inclusive).

Further details will also be available on website of the Company i.e. www.sharonbio.com as well as website of the Stock Exchanges www.nseindia.com & www.bseindia.com

By *Sharon Bio-Medicine Ltd.*

Sd/-

Deepali Bhatia

**Company Secretary
& Compliance Officer**

Date: February 14, 2018

Place: Mumbai